Citations

Clear

6273 citation(s) found for "To, Andrew".

Positive Identification of Genetic Causes of FSGS Increases with Proper Patient Selection
Zand, Ladan , Erickson, Stephen B., Prochnow, Carri A., Ters, Mireille El , Kukla, Aleksandra , Greene, Eddie L., Hernandez, Loren P. Herrera , Sethi, Sanjeev , Miao, Jing , Vairo, Filippo Pinto e , Hogan, Marie C. , Bentall, Andrew , Fervenza, Fernando C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 513-513

10.1681/asn.20203110s1513a Get It

Automated Instance Cyst Segmentation of Polycystic Kidneys in MRIs
Gregory, Adriana , Anaam, Deema , Vercnocke, Andrew J. , Edwards, Marie E., Kline, Timothy L. , Chebib, Fouad T. , Torres, Vicente E. , Harris, Peter C. , Erickson, Bradley J.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 499-499

10.1681/asn.20203110s1499a Get It

Hematopoietic Stem-Cell Transplantation: Exploring the Latest Advances and Gaps in Disparities, Psychosocial and Symptom Management Interventions, and Chronic Graft-Versus-Host Disease Care
Trunk, Andrew D. , Budvytyte, Laura, Khera, Nandita , Hamilton, Betty K. , Islam, N. , Islam, Nadia S, Islam, Nadia , Guo, Michelle , Islam, Nadia S., Amonoo, Hermioni Lokko

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 16, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_432186 | PMID 38754066 Get It

Although allogeneic hematopoietic cell transplantation (HCT) offers a potential for cure for many patients with advanced hematologic malignancies and bone marrow failure or immunodeficiency syndromes, it is an intensive treatment and accompanied by short- and long-term physical and psychological symptoms requiring specialized care. With substantial advances in therapeutic approaches for HCT and supportive care, HCT survivors experience less morbidity and mortality. However, disparities in both HCT access and outcomes persist, and HCT survivors and their caregivers often lack access to much-needed psychosocial care. Additionally, more medical and psychosocial resources are needed to holistically care for HCT survivors with chronic graft-versus-host disease (GVHD). Hence, this chapter focuses on three areas pertaining to advances and gaps in HCT care: disparities in access to and outcomes of HCT, psychosocial and physical symptom management with supportive care interventions, and GVHD prevention and management.
Palliative Care for Patients With Cancer: ASCO Guideline Update
Sanders, Justin J. , Temin, Sarah , Ghoshal, Arunangshu , Alesi, Erin R. , Ali, Zipporah , Chauhan, Cynthia, Cleary, James F. , Firn, Janice , Jones, J , Litzow, Mark R. , Lundquist, Debra , Mardones, Mabel Alejandra, Rabow, Michael W. , Rosa, William E. , Ghoshal, Arun , Ali, Zipporah Vunoro , Epstein, Andrew S , Jones, Joshua A , Litzow, Mark R. , Lundquist, Debra , Nipp, Ryan , Rosa, William E , Zimmermann, Camilla , FERRELL, BETTY ROLLING , Nipp, Ryan David

Mayo Clinic

Journal of Clinical Oncology | May 15, 2024 | Volume: 42 | Issue: 19 | Pages: 2336-2357

10.1200/jco.24.00542 | PMID 38748941 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE To provide evidence-based guidance to oncology clinicians, patients, nonprofessional caregivers, and palliative care clinicians to update the 2016 ASCO guideline on the integration of palliative care into standard oncology for all patients diagnosed with cancer. METHODS ASCO convened an Expert Panel of medical, radiation, hematology-oncology, oncology nursing, palliative care, social work, ethics, advocacy, and psycho-oncology experts. The Panel conducted a literature search, including systematic reviews, meta-analyses, and randomized controlled trials published from 2015-2023. Outcomes of interest included quality of life (QOL), patient satisfaction, physical and psychological symptoms, survival, and caregiver burden. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 52 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations address the integration of palliative care in oncology. Oncology clinicians should refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams that provide outpatient and inpatient care beginning early in the course of the disease, alongside active treatment of their cancer. For patients with cancer with unaddressed physical, psychosocial, or spiritual distress, cancer care programs should provide dedicated specialist palliative care services complementing existing or emerging supportive care interventions. Oncology clinicians from across the interdisciplinary cancer care team may refer the caregivers (eg, family, chosen family, and friends) of patients with cancer to palliative care teams for additional support. The Expert Panel suggests early palliative care involvement, especially for patients with uncontrolled symptoms and QOL concerns. Clinicians caring for patients with solid tumors on phase I cancer trials may also refer them to specialist palliative care. Additional information is available at www.asco.org/supportive-care-guidelines .
Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial
Kawut, Steven M. , Feng, Rui , Ellenberg, Susan S. , Zamanian, Roham T. , Bull, Todd M., Chakinala, Murali M. , Mathai, Stephen C. , Hemnes, Anna R. , Lin, Grace , Andrew, Ruth , Stasinopoulos, Ioannis , Shou, Haochang , Song, Nianfu, Moutchia, Jude , Hemnes, Anna , Austin, Eric , Minhas, Jasleen , Ventetuolo, Corey E , Kawut, Steven M , Mathai, Stephen C , Doyle, Margaret F. , MacLean, Margaret R. , DeMichele, Angela , Minhas, Jasleen , Song, Nianfu, Ventetuolo, Corey E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 15, 2024 | Volume: 210 | Issue: 9 | Pages: 1143-1151

10.1164/rccm.202402-0371oc | PMID 38747680 Get It

Abstract Rationale Inhibition of aromatase with anastrozole reduces pulmonary hypertension in experimental models. Objectives We aimed to determine whether anastrozole improved the 6-minute-walk distance (6MWD) at 6 months in pulmonary arterial hypertension (PAH). Methods We performed a randomized, double-blind, placebo-controlled phase II clinical trial of anastrozole in subjects with PAH at seven centers. Eighty-four postmenopausal women with PAH and men with PAH were randomized in a 1:1 ratio to receive anastrozole 1 mg or placebo by mouth daily, stratified by sex using permuted blocks of variable sizes. All subjects and study staff were masked. The primary outcome was the change from baseline in 6MWD at 6 months. By intention-to-treat analysis, we estimated the treatment effect of anastrozole using linear regression models adjusted for sex and baseline 6MWD. Assuming 10% loss to follow-up, we anticipated having 80% power to detect a difference in the change in 6MWD of 22 meters. Measurements and Main Results Forty-one subjects were randomized to placebo and 43 to anastrozole, and all received the allocated treatment. Three subjects in the placebo group and two in the anastrozole group discontinued the study drug. There was no significant difference in the change in 6MWD at 6 months (placebo-corrected treatment effect, −7.9 m; 95% confidence interval, −32.7 to 16.9; P = 0.53). There was no difference in adverse events between the groups. Conclusions Anastrozole did not show a significant effect on 6MWD compared with placebo in postmenopausal women with PAH and in men with PAH. Anastrozole was safe and did not have adverse effects. Clinical trial registered with www.clincialtrials.gov (NCT03229499).
Optimizing pediatric periprocedural pain management part I—Evolving ethics and topical anesthetics
Henkel, Emily , Haller, Courtney N. , Diaz, Lucia Z., Ricles, Victoria , Grossman, Ashley V. Wong, Krakowski, Andrew C. , Wong Grossman, Ashley V, Nemergut, Michael E. , Grossman, Ashley Wong

Mayo Clinic

Pediatric Dermatology | May 14, 2024 | Volume: 41 | Issue: 4 | Pages: 577-587

10.1111/pde.15635 | PMID 38743586 Get It

AbstractPediatric procedure‐related pain management is often incompletely understood, inadequately addressed, and critical in influencing a child's lifelong relationship with the larger health care community. We highlight the evolution of ethics and expectations around optimizing periprocedural pain management as a fundamental human right. We investigate the state‐of‐the‐art of topical anesthetics, reviewing their mechanisms of action and providing comparisons of their relative safety and efficacy data to help guide clinical selection. In total, this two‐part review offers a combination of conventional approaches and innovative techniques that should be used multimodally—in series and in parallel—to help optimize pain management and provide alternatives to sedation medication and general anesthesia.
A rare case of aortitis presenting as chest pain: a case report and literature review
Ahmed, Hasaan , Palicherla, Anirudh , Kalathil, Ruth Ann Mathew, Vaza, Shivani, Kabach, Amjad , Aboeata, Ahmed, Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

Annals of Medicine & Surgery | May 14, 2024 | Volume: 86 | Issue: 7 | Pages: 4165-4169

10.1097/ms9.0000000000002140 | PMID 38989168 Get It

Introduction and importance: Chest pain is a frequent reason patients seek medical attention. The broad spectrum of potential etiologies makes determining the underlying cause of chest pain complex. Among cardiovascular etiologies, aortitis is a rare but life-threatening possibility that should be considered in the differential diagnosis. Case presentation: A 53-year-old female with a history of smoking presented with progressively worsening chest and epigastric pain over several weeks. She had seen multiple physicians previously for the same symptoms with unremarkable work-ups. Physical examination was notable for severe tenderness upon palpation of her lower abdomen. The electrocardiogram and troponins were unremarkable. Computed tomography of the abdomen revealed aneurysmal dilatation of the abdominal aorta, soft tissue thickening, and surrounding inflammatory stranding, consistent with aortitis. Infectious and autoimmune work-ups were unremarkable. Intravenous steroids were initiated, and her symptoms improved significantly. Her aortitis was attributed to inflammation secondary to chronic smoking. Clinical discussion: Aortitis is a rare condition with varied clinical presentations. Etiologies of aortitis include infection and non-infectious inflammation. Diagnosis of aortitis requires a thorough clinical assessment and prompt imaging of the aorta, with computed tomography being the preferred imaging modality. Conclusion: Evaluation for cardiovascular chest pain must extend beyond an electrocardiogram and troponin level. Imaging should be considered in patients with atypical symptoms. Aortitis is a rare but important diagnosis requiring immediate treatment.
27. The Fate Of The Frozen Bone Flap: Quantitative Assessment Of Bone Flap Resorption Following Delayed Autologous Cranioplasty
Cherukuri, Sai , Zheng, Eugene, Emanuels, Andrew F., Bite, Uldis, Emanuels, Andrew, Gompel, Jamie J. Van , Morris, Jonathan M. , Mardini, Samir , Gibreel, Waleed

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 10, 2024 | Volume: 12 | Issue: S5 | Pages: 18-19

10.1097/01.gox.0001018124.22700.84 Get It

Utilizing median and maximum QTc values improves prediction of breakthrough cardiac events in pediatric long QT syndrome
Rohatgi, Ram K., Tseng, Andrew S. , Sugrue, Alan , Lee, Alexander T. , Wackel, Phillip L., Cannon, Bryan C. , Bos, J. Martijn , Ackerman, Michael J. , Sugrue, Alan , Wackel, Philip , Ackerman, Michael J , Tseng, A S , Bos, Johan M , Scott, Christopher G.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 10, 2024 | Volume: 35 | Issue: 7 | Pages: 1370-1381

10.1111/jce.16293 | PMID 38725227 Get It

AbstractIntroductionAlthough prior studies indicate that a QTc > 500 ms on a single baseline 12‐lead electrocardiogram (ECG) is associated with significantly increased risk of arrhythmic events in long QT syndrome (LQTS), less is known about the risk of persistent QT prolongation. We sought to determine QTc persistence and its prognostic effect on breakthrough cardiac events (BCEs) among pediatric patients treated for LQTS.MethodsWe performed a retrospective analysis of 433 patients with LQTS evaluated, risk‐stratified, and undergoing active guideline‐based LQTS treatment between 1999 and 2019. BCEs were defined as arrhythmogenic syncope/seizure, sudden cardiac arrest (SCA), appropriate VF‐terminating ICD shock, and sudden cardiac death (SCD).ResultsDuring the median follow‐up of 5.5 years (interquartile range [IQR] = 3–9), 32 (7%) patients experienced a total of 129 BCEs. A maximum QTc threshold of 520 ms and median QTc threshold of 490 ms were determined to be strong predictors for BCEs. A landmark analysis controlling for age, sex, genotype, and symptomatic status demonstrated models utilizing both the median QTc and maximum QTc demonstrated the highest discriminatory value (c‐statistic = 0.93–0.95). Patients in the high‐risk group (median QTc > 490 ms and maximum QTc > 520 ms) had a significantly lower BCE free survival (70%–81%) when compared to patients in both medium‐risk (93%–97%) and low‐risk (98%–99%) groups.ConclusionsThe risk of BCE among patients treated for LQTS increases not only based upon their maximum QTc, but also their median QTc (persistence of QTc prolongation). Patients with a maximum QTc > 520 ms and median QTc > 490 ms over serial 12‐lead ECGs are at the highest risk of BCE while on guideline‐directed medical therapy.
Editorial Comment
Lyon, Timothy D. , Zganjar, Andrew J., Lyon, Timothy D

Mayo Clinic

Journal of Urology | May 9, 2024 | Volume: 211 | Issue: 6 | Pages: 752-752

10.1097/ju.0000000000003933 | PMID 38721934 Get It